The big pharma company Bristol Myers Squibb (BMS) committed up to $180 million for a phase 1-ready antibody-drug conjugate (ADC) for the treatment of blood cancer from the U.S.-South Korean biotech company Orum Therapeutics.
Related Keywords
, Joo Lee , Bristol Myers Squibb , Drug Administration , Dual Precision Targeted Protein Degradation , Sung Joo Lee , Orum Therapeutics , Antibody Drug Conjugates , Pipelines , Cell Amp Gene Therapies , Ncology , Blood Cancers , Research , Funding ,
comparemela.com © 2020. All Rights Reserved.